BIBProShares Ultra Nasdaq Biotechnology
The schedule
- Thu15Oct
A critical window where mid-to-small cap constituents historically announce secondary offerings to extend cash runways.
- Mon9Nov
Gilead Sciences' Q3 results and critical forward commentary on defending its HIV franchise against generic entry.
- Tue15Dec
Alnylam's PDUFA date for a major RNA interference therapy, setting a bellwether for FDA approval standards.
- Sun27Dec
Critical mid-to-late stage clinical data release for Amgen's highly anticipated obesity and weight-loss candidate.
- Tue12Jan
The annual J.P. Morgan Healthcare Conference, traditionally the largest venue for biotech M&A announcements and 2027 strategic pivots.
- Wed17Feb
Amgen's Q4 print, revealing the broader commercial trajectory of its GLP-1/GIP portfolio and core mature products.
Past
- Wed22Jul
ProShares' release of Q2 ETF earnings, distributions, and semi-annual fundamental tracking metrics.
- Sat20Jun
Actual outcome: Bull · $94.16 at outcome
The leveraged biotech ETF surged as the broader sector rallied and specific overhangs on key components were resolved. Guardant Health (GH) successfully addressed its cash runway and debt refinancing needs on favorable terms, avoiding the severe equity dilution that investors had feared. This resolution of GH's balance sheet pressures contributed to the positive sentiment, driving the ETF well past its bull target.
(Driven by GH) With $1.67B in debt and negative free cash flow, GH faces pressure to refinance or raise equity from the $104.50 level.
